Psilocybin
As of the edition of 20 October 2026, Psilocybin is a small molecule: in active development; acts on HTR2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 240, 17 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Cancer; Injuries; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Psilocybin.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 7 | 3 | 1 |
| Phase 1 | 91 | 30 | 51 | 8 |
| Phase 2 | 125 | 30 | 73 | 8 |
| Phase 3 | 11 | 2 | 9 | 0 |
| All trials | 240 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| COMPASS Pathways | Lead sponsor of trials | 2019 to now |
| Beckley Psytech | Lead sponsor of trials | 2021 to now |
| Diamond Therapeutics | Lead sponsor of trials | 2021 to now |
| TRYP Therapeutics | Lead sponsor of trials | 2022 to now |
| Clairvoyant Therapeutics | Lead sponsor of trials | 2022 to now |
| Halucenex Life Sciences | Lead sponsor of trials | 2022 to now |